Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRadimed Corporation filings document the public-company reporting for a Nasdaq-listed medical-device manufacturer focused on MRI-compatible infusion and patient-monitoring systems. Form 8-K reports furnish quarterly and annual operating results, dividend announcements, guidance updates and other material events tied to the company’s common stock.
Proxy and governance filings describe annual meeting proposals, director elections, auditor ratification, executive compensation, board committee matters and shareholder voting results. Other 8-K disclosures record board composition changes and related committee assignments, providing formal records of governance and capital-structure matters for IRMD.
IRADIMED CORPORATION will hold its 2026 annual stockholder meeting on June 23, 2026 in Orlando. Investors are being asked to elect five directors, ratify RSM US LLP as auditor for 2026, and approve a non-binding say-on-pay vote on 2025 executive compensation.
The company had gross revenue of $83.8 million in 2025, net income of $22.5 million, and year-end cash of $51.2 million. It paid $15.0 million in dividends and invested $7.8 million toward a new headquarters and manufacturing facility funded from cash flow. Audit fees to RSM for 2025 were $303,664.
CEO Roger Susi earned total 2025 compensation of $780,598, including a $395,000 cash bonus; CFO John Glenn earned $609,994 and Chief Commercial Officer Jeff Chiprin $529,360. At the April 24, 2026 record date, 12,783,035 common shares were outstanding, with Susi beneficially owning about 34.6%.
IRADIMED CORP insider reporting person Roger E. Susi, who serves as CEO, President, Chairman and a 10% owner, reported indirect open-market sales of Common Stock through the Phillip Susi 2008 Dynasty Trust.
Across seven transactions on April 27–28, 2026, that trust sold a total of 7,500 shares at weighted average prices ranging from about $84 to $90 per share, leaving 2,197,905 shares held indirectly by that trust. Additional indirect holdings include 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of April 27, 2026.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a pre-arranged program rather than discretionary timing. It also states that the reporting person disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.
IRADIMED CORP insider Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of common stock on April 20–21, 2026. Reported sale prices include $93.90, $93.14, $92.66, $91.65, $90.60 and $89.73 per share.
The filing notes these transactions were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. Post‑transaction line items show the trusts continuing to hold sizable indirect positions, with balances ranging from hundreds of thousands to over two million shares.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of 7,500 shares of common stock on April 13–14, 2026. The transactions were executed by the Phillip Susi 2008 Dynasty Trust at weighted average prices around $92–$94 per share under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, the Phillip Susi 2008 Dynasty Trust held 2,210,000 shares indirectly, while separate indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust as of April 13, 2026.
IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7. Reported sale prices ranged from $94.36 to $96.78 per share, and the filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following these sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, and states that Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock. The Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of IRMD on March 30, 2026 in three transactions at weighted average prices of $94.81, $95.66 and $96.53 per share. After these trades, the Dynasty Trust holds 2,225,000 shares, while additional indirect holdings reported include 162,950 shares in the Roger E. Susi Revocable Trust and 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan, and the reporting person disclaims beneficial ownership of the securities beyond his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported open-market sales of 7,500 shares of Common Stock, executed indirectly through the Phillip Susi 2008 Dynasty Trust. The sales occurred on March 23–24, 2026 at prices around $100 per share, including transactions at $99.58, $100.03, $100.71, $100.70 and $102.02 per share.
A footnote states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a scheduled selling program rather than ad hoc market timing. After the transactions, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares, while other indirect holdings included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust as of March 23, 2026. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.